The revolutionary weight-loss drugs are a game-changer, but there's a catch: you might need to take them forever.
Published on January 8, 2026, a new study reveals a critical detail about the latest weight-loss medications. These drugs, including popular names like Ozempic, Wegovy, and Mounjaro, offer incredible benefits. They can lead to significant weight loss and improve heart health, but here's the kicker: the advantages vanish if you stop taking them. This is not entirely unexpected, as these medications treat biological conditions, and long-term use is recommended.
This research, published in the British Medical Journal and led by Oxford University, shows that people who discontinue these GLP-1 agonist drugs regain weight much faster than those who rely on conventional diet programs.
But here's where it gets controversial... Stopping the medication leads to an average weight regain of 400 grams per month, with all lost weight likely to return in under two years. This is almost four times quicker than the weight regain experienced by those who lose weight through diet and exercise alone.
The study analyzed 37 different studies, involving a total of 9,341 participants dealing with overweight or obesity. It found that positive effects, such as reduced cholesterol and blood pressure, were reversed after stopping the medication. Risks for diabetes and heart disease were predicted to return to pre-treatment levels within two years.
These GLP-1 receptor agonists work by mimicking a natural gut hormone. They stimulate insulin release, slow down how quickly your stomach empties, and reduce your appetite. This leads to lower blood sugar levels and weight loss. Studies have also shown these drugs offer protective benefits for the heart, kidneys, and liver.
Experts, like Sydney University endocrinologist Associate Professor Samantha Hocking, emphasize that obesity is a biological condition. The body responds to weight loss by increasing hunger hormones and decreasing satiety hormones, leading to increased appetite and hunger. Without these medications, the body works to regain the lost weight.
And this is the part most people miss... The study highlights the wide-ranging health benefits of these new medications. They have been shown to improve liver health, kidney function, and sleep apnea. Moreover, they reduce the risk of cardiovascular disease. Continuous use of semaglutide (Ozempic/Wegovy) over four years reduced major cardiovascular disease events in individuals with existing cardiovascular disease.
Associate Professor Dominika Kwasnicka, a behavioral scientist at the University of Melbourne, points out that the study doesn't suggest the medications don't work, but rather that they act on biological pathways, not behavioral changes.
For Australians, this has significant implications. Access to these medications is expanding, often with substantial out-of-pocket costs and limited follow-up care. The study supports the need for comprehensive, long-term care models that include behavioral support and realistic discussions about the duration of treatment.
The study also found that it's common for people to stop taking these medications within the first year, emphasizing the need for caution when considering short-term use.
Professor Garron Dodd, head of the metabolic neuroscience laboratory at the University of Melbourne, highlights that while these drugs have changed the conversation around obesity and type 2 diabetes treatment, they are not a 'silver bullet.' He believes they are an exciting start, opening up new possibilities in the field. Research is underway to understand why the body defends its weight, with sustainable combination treatments likely to emerge in the future. These treatments could reshape how the brain interprets energy balance, not just how much people eat.
What are your thoughts? Do you think the long-term commitment to these medications is a fair trade-off for the health benefits? Share your opinions in the comments below!
